S&P 500

5.431,60

0,00%

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Salarius Pharmaceuticals Inc (SLRX)
Salarius Pharmaceuticals Inc (SLRX) Notícias

SLRX

Salarius Pharmaceuticals (SLRX)

Salarius Pharmaceuticals Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:SLRX

1 2 3 4 5 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
17/06/2024	09:11	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
17/06/2024	09:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
17/06/2024	09:00	GlobeNewswire Inc.	Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
12/06/2024	09:00	GlobeNewswire Inc.	Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
13/05/2024	17:17	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
22/03/2024	17:05	GlobeNewswire Inc.	Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
22/02/2024	18:29	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
22/02/2024	10:00	GlobeNewswire Inc.	Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
16/01/2024	10:00	GlobeNewswire Inc.	Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
03/01/2024	10:30	GlobeNewswire Inc.	Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
07/11/2023	10:30	GlobeNewswire Inc.	Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
27/10/2023	16:57	Edgar (US Regulatory)	Form SC 13D - General statement of acquisition of beneficial ownership	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
10/08/2023	17:05	GlobeNewswire Inc.	Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
08/08/2023	17:05	GlobeNewswire Inc.	Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
11/07/2023	09:30	GlobeNewswire Inc.	Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
12/06/2023	09:00	GlobeNewswire Inc.	Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
08/06/2023	07:02	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
07/06/2023	08:28	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
01/06/2023	18:02	Edgar (US Regulatory)	Securities Registration Statement (simplified Form) (s-3/a)	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
26/05/2023	18:03	Edgar (US Regulatory)	Securities Registration Statement (simplified Form) (s-3)	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
16/05/2023	17:34	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
16/05/2023	17:05	GlobeNewswire Inc.	Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
12/05/2023	09:00	GlobeNewswire Inc.	Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
11/05/2023	09:00	GlobeNewswire Inc.	Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
09/05/2023	09:00	GlobeNewswire Inc.	FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
01/05/2023	09:30	GlobeNewswire Inc.	Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
01/05/2023	09:05	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
01/05/2023	09:03	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
20/04/2023	09:30	GlobeNewswire Inc.	Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting	NASDAQ:SLRX	Salarius Pharmaceuticals Inc
04/04/2023	17:02	GlobeNewswire Inc.	Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference	NASDAQ:SLRX	Salarius Pharmaceuticals Inc